PMID- 14642022
OWN - NLM
STAT- MEDLINE
DCOM- 20031219
LR  - 20131121
IS  - 1044-5463 (Print)
IS  - 1044-5463 (Linking)
VI  - 13
IP  - 3
DP  - 2003 Fall
TI  - The Kutcher Adolescent Depression Scale: assessment of its evaluative properties 
      over the course of an 8-week pediatric pharmacotherapy trial.
PG  - 337-49
AB  - OBJECTIVE: Self-report instruments commonly used to assess depression in 
      adolescents have limited or unknown psychometric properties in this age group. We 
      report the evaluative properties of the Kutcher Adolescent Depression Scale 
      (KADS), a self-report scale designed specifically for identifying depressed 
      adolescents and for monitoring symptom severity over time. METHODS: One hundred 
      and six adolescents with major depression disorder (MDD) enrolled in an 8-week, 
      double-blind, placebo-controlled study of paroxetine. Efficacy assessments were 
      conducted on days 0 (baseline), 7, 14, 21, 28, 42, and 56 using the self-rated 
      KADS and the clinician-rated Children's Depression Rating Scale-Revised (CDRS-R), 
      Clinical Global Impression (CGI) of severity, and Global Assessment of 
      Functioning (GAF) scale. The data were initially examined to establish which of 
      the 16 KADS items showed greatest sensitivity to change. Subsequent analyses then 
      compared the evaluative properties of three versions of the KADS: the full-length 
      KADS, a six-item subscale previously established as a screening tool, and an 
      11-item subscale optimized for sensitivity to change. RESULTS: Within-subject 
      correlations among subjects' KADS scores and their clinician-rated scale scores 
      showed that clinician-rated changes in severity were significantly better 
      corroborated by the 11-item KADS (mean correlations with the CDRS-R, CGI, and 
      GAF: r = 0.69, 0.60, and -0.70, respectively) than by the six-item KADS (r = 
      0.62, 0.56, and -0.63, respectively) and at least as well corroborated as by the 
      full-length KADS (r = 0.64, 0.56, and -0.67, respectively). Furthermore, in terms 
      of mean percentage change in scores from day 0 to day 56, the 11-item KADS (59%) 
      significantly outperformed the full-length KADS (46%) and all three 
      clinician-rated scales (43%, 37%, and 29%, respectively) and at least matched the 
      performance of the six-item KADS (56%). CONCLUSIONS: These results suggest that 
      the 11-item self-rated KADS is a sensitive measure of treatment outcome in 
      adolescents diagnosed with MDD.
FAU - Brooks, Sarah J
AU  - Brooks SJ
AD  - Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Krulewicz, Stanley P
AU  - Krulewicz SP
FAU - Kutcher, Stan
AU  - Kutcher S
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 41VRH5220H (Paroxetine)
SB  - IM
MH  - Adolescent
MH  - Antidepressive Agents, Second-Generation/*therapeutic use
MH  - Child
MH  - Depression/*drug therapy/*psychology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Paroxetine/*therapeutic use
MH  - *Psychiatric Status Rating Scales
MH  - Reproducibility of Results
EDAT- 2003/12/04 05:00
MHDA- 2003/12/20 05:00
CRDT- 2003/12/04 05:00
PHST- 2003/12/04 05:00 [pubmed]
PHST- 2003/12/20 05:00 [medline]
PHST- 2003/12/04 05:00 [entrez]
AID - 10.1089/104454603322572679 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2003 Fall;13(3):337-49. doi: 
      10.1089/104454603322572679.